Literature DB >> 16259581

Review of immediate-release omeprazole for the treatment of gastric acid-related disorders.

Donald Castell1.   

Abstract

Immediate-release omeprazole (Zegerid, Santarus) is the first immediate-release oral proton pump inhibitor to reach the market. As a powder formulation for oral suspension, it is indicated for the treatment of gastroesophageal reflux disease, erosive oesophagitis, duodenal ulcer and gastric ulcer, and is the only proton pump inhibitor approved for the reduction of risk of upper gastrointestinal bleeding in critically ill patients. Administration of immediate-release omeprazole at bedtime results in a rapid and sustained elevation of gastric pH, and seems to provide better night time control of gastric acidity than that observed with conventional morning dosing of delayed-release proton pump inhibitors. The immediate-release formulation may provide a good treatment option for patients who require flexible dosing, quick onset of action and nocturnal gastric acid control.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16259581     DOI: 10.1517/14656566.6.14.2501

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  10 in total

Review 1.  Gastroesophageal reflux disease and sleep disturbances.

Authors:  Yasuhiro Fujiwara; Tetsuo Arakawa; Ronnie Fass
Journal:  J Gastroenterol       Date:  2012-05-17       Impact factor: 7.527

Review 2.  Guide to the use of proton pump inhibitors in adult patients.

Authors:  Vandana Boparai; Jaishree Rajagopalan; George Triadafilopoulos
Journal:  Drugs       Date:  2008       Impact factor: 9.546

3.  Once-daily omeprazole/sodium bicarbonate heals severe refractory reflux esophagitis with morning or nighttime dosing.

Authors:  Diana M Orbelo; Felicity T Enders; Yvonne Romero; Dawn L Francis; Sami R Achem; Tushar S Dabade; Michael D Crowell; Debra M Geno; Ramona S DeJesus; Vikneswaran Namasivayam; Steven C Adamson; Amindra S Arora; Andrew J Majka; Jeffrey A Alexander; Joseph A Murray; Matthew Lohse; Nancy N Diehl; Mary Fredericksen; Kee Wook Jung; Margaret S Houston; Angela E O'Neil; David A Katzka
Journal:  Dig Dis Sci       Date:  2014-01-22       Impact factor: 3.199

4.  Synthesis and Investigation of S-Substituted 2-Mercaptobenzoimidazoles as Inhibitors of Hedgehog Signaling.

Authors:  Simone Gräßle; Steven Susanto; Sonja Sievers; Emel Tavsan; Martin Nieger; Nicole Jung; Stefan Bräse
Journal:  ACS Med Chem Lett       Date:  2017-07-28       Impact factor: 4.345

Review 5.  Insights into the future of gastric acid suppression.

Authors:  Kenneth R DeVault; Nicholas J Talley
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-09       Impact factor: 46.802

6.  Pharmacokinetics and Pharmacodynamics of Esomeprazole/Sodium Bicarbonate Immediate-Release Capsules in Healthy Chinese Volunteers: A Cross-Over, Randomized Controlled Trial.

Authors:  Shan Jing; Yue Zhu; Wenfang Liu; Kexu Yang; Lili Hu; Dan Deng; Chunyan Lu; Yang Lin
Journal:  Adv Ther       Date:  2021-02-11       Impact factor: 3.845

Review 7.  International Consensus on Guiding Recommendations for Management of Patients with Nonsteroidal Antiinflammatory Drugs Induced Gastropathy-ICON-G.

Authors:  Richard Hunt; Leonid B Lazebnik; Yury C Marakhouski; Mircea Manuc; Ramesh Gn; Khin S Aye; Dmitry S Bordin; Natalia V Bakulina; Baurzhan S Iskakov; Abror A Khamraev; Yurii M Stepanov; Reidwaan Ally; Amit Garg
Journal:  Euroasian J Hepatogastroenterol       Date:  2019-02-01

8.  The safety, pharmacodynamics, and pharmacokinetics of immediate-release formulation containing esomeprazole 20 mg/sodium bicarbonate 800 mg in healthy adult male.

Authors:  Dasohm Kim; Min Soo Park; Byung Won Yoo; Taegon Hong; Shin Jung Park; Choon Ok Kim
Journal:  Drug Des Devel Ther       Date:  2019-09-03       Impact factor: 4.162

9.  A versatile, compartmentalised gut-on-a-chip system for pharmacological and toxicological analyses.

Authors:  Pim de Haan; Milou J C Santbergen; Meike van der Zande; Hans Bouwmeester; Michel W F Nielen; Elisabeth Verpoorte
Journal:  Sci Rep       Date:  2021-03-01       Impact factor: 4.379

10.  Comparative Pharmacokinetics/Pharmacodynamics of Fixed-Dose Combination of Esomeprazole and Calcium Carbonate (AD-206) to the Conventional Esomeprazole.

Authors:  Sungyeun Bae; Jihoon Kwon; Si-Beum Lee; In-Jin Jang; Kyung-Sang Yu; SeungHwan Lee
Journal:  Drug Des Devel Ther       Date:  2021-12-21       Impact factor: 4.162

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.